Close Menu

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) - Axis-Shield said today that it has signed an agreement with Bio-Rad Laboratories for an option to commercialize heparin binding protein as a marker of severe sepsis.

Under the terms of this agreement, Bio-Rad will have the right to develop the HBP marker for use on its proprietary laboratory instruments globally.

Additional terms of the deal were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A new study finds that three dimensional facial scans may be able to aid in diagnosing rare genetic diseases.

The Lancet and the New England Journal of Medicine have retracted two COVID-19 papers due to concerns about the data used in their analyses.

Lawmakers plan to introduce a bill that aims to prevent the theft of US-funded research, according to the Wall Street Journal.

In Science this week: analysis of ancient Caribbean islanders' genomes suggests at least three waves of migration into the region,  DNA barcoding of microbial spores, and more.

Jul
15
Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.